Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Provided By GlobeNewswire
Last update: Mar 27, 2024
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801
Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial
Read more at globenewswire.com
